Pharma Giants Invest Billions in US
The strengthening of the presence of global pharmaceutical companies in the United States is reflected in investments approaching $500 billion, aimed at enhancing manufacturing capabilities, advancing scientific research, and reducing supply chain risks. These investments include plans from companies such as Pfizer, Eli Lilly, Johnson & Johnson, Roche, AstraZeneca, Novartis, Sanofi, and others, and range from building new factories, expanding existing facilities, to improving research infrastructure. These steps are part of the companies' efforts to expand their presence in the American market and achieve further scientific and industrial advancements, while also addressing challenges related to tariffs and meeting local demand.
Notice: This Is an AI-Generated Summary
Comments (0)